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Phase I Study of Radical Thoracic Radiation, Weekly
Irinotecan, and Cisplatin in Locally Advanced Non-small
Cell Lung Carcinoma
Corey J. Langer, MD, Robert Somer, MD, Samuel Litwin, PhD, Steven Feigenberg, MD,
Benjamin Movsas, MD, Christine Maiale, RN, Eric Sherman, MD, Michael Millenson, MD,
Nicos Nicoloau, MD, Chao Huang, MD, and Joseph Treat, MD
Background: Irinotecan and cisplatin individually are active in
non-small cell lung carcinoma (NSCLC). Each is synergistic with
radiation. Dosages of 65 mg/m2 of irinotecan and 30 mg/m2 of
cisplatin Q weekly times four every 6 weeks yielded a 36% response
rate and median survival of 11.6 months in advanced NSCLC
(Jagasia et al.; Clinical Cancer Reserch 7: 68, 2001). A weekly
schedule for each agent (versus less frequent doses) limits toxicity
and increases the opportunity for radiosensitization.
Materials and Methods: We initiated a phase I study of weekly
irinotecan and cisplatin during radical thoracic radiation (TRT).
Cisplatin was fixed at 25 mg/m2 Q weekly times seven. Irinotecan
was dosed initially at 30 mg/m2 per week for 7 weeks and was
increased by 10 mg/m2 per week in three- to six-patient cohorts.
TRT was administered in 34 single daily fractions to 63 Gy.
Eligibility stipulated locally advanced NSCLC; Eastern Cooperative
Oncology Group performance status 0 to 1; 10% unintended
weight loss; and adequate physiologic indices.
Results: Fifteen patients were accrued: nine were stage IIIB, five
were stage IIIA, and one had isolated mediastinal node recurrence
after prior surgery. Median age was 65 years (range, 47–77). Seven
patients received irinotecan at a dose of 30 mg/m2 per week; (dose
level 1). Seven other patients received irinotecan at a dose of 40
mg/m2 per week; (dose level 2). The one other patient received
irinotecan in doses of 50 mg/m2 per week; (dose level 3). Neutro-
penic fever occurred in one patient each at dose levels 1 and 2.
Grade 4 neutropenia occurred in three patients at each dose level.
Transient grade 3 diarrhea occurred in one patient at dose level 1.
Esophagitis of grade 3 or higher occurred in one patient each at dose
levels 2 and 3. There was one late grade 3 pneumonitis at dose level
2. Delivered irinotecan dose intensity for dose level 1 was 27 mg/m2
per week; for dose level 2, it was 31.4 mg/m2 per week. Nine of 13
evaluable patients (69%) responded. At median potential follow-up
of 5 years, 14 have progressed, and 11 have died. Projected median
survival is 28 months; one patient who was treated for mediastinal
node recurrence remains free from progression at 6 years.
Conclusion: Weekly irinotecan and cisplatin combined with rad-
ical TRT (63 Gy) is active and fairly well tolerated in locally
advanced NSCLC. In combination with fixed-dose cisplatin (25
mg/m2 per week), the maximum-tolerated dose of irinotecan is 30
mg/m2 per week.
Key Words: Phase I study, Locally advanced NSCLC, Radical
thoracic radiation, Irinotecan, Cisplatin.
(J Thorac Oncol. 2007;2: 203–209)
Lung cancer remains the leading cause of malignancy-related mortality in the United States, and it is a burgeon-
ing health problem worldwide, with over a million cases
diagnosed yearly.1 In 2006, more than 170,000 Americans are
expected to be diagnosed with lung cancer. The 5-year
survival rate remains deplorable at 15%, although this figure
represents an improvement over the past 30 years. Non-small
cell lung carcinoma (NSCLC) is often systemic at diagnosis,
but a sizable proportion of patients, estimated in the range of
30% to 40%, have locally advanced disease at presentation
and are potentially amenable to curative chemotherapy and
radiation. Until 1990, radical thoracic radiation (TRT) alone
to the primary tumor and its hilar and mediastinal drainage
was the standard of treatment2–8 Nevertheless, median sur-
vival time at 8 to 10 months was poor, with 2-year survival
rates of less than 15% to 20%; long-term cure rates were less
than 5%. In the past decade and a half, significant therapeutic
advances have been reported. The Cancer and Leukemia
Group B standard of neoadjuvant vinblastine and cisplatin,
followed by TRT, demonstrated a significant improvement in
survival, with a long-term survival rate of 16% compared
with 7% for TRT alone.9 Other studies have shown a similar
advantage for sequential chemotherapy and radiation com-
pared with radiation alone, although the 5-year survival rate
has not been as impressive.10–14
Contemporaneously, the European Organisation for Re-
search and Treatment of Cancer and other investigators have
shown a clear-cut survival advantage for concurrent platinat-
ing chemotherapy and radiation compared with radiation
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alone.15–17 More recently, in a randomized phase III trial, Furuse
and colleagues18 demonstrated a survival advantage for concur-
rent chemotherapy and split-course radiation versus sequential
chemotherapy using an identical regimen and full-dose uninter-
rupted radiation. The 5-year survival rate for the concurrent
approach was 16%, nearly double that observed in the control
group. The results of Radiation Therapy Oncology Group trial
9410, a three-arm trial comparing sequential chemoradiation
with two different iterations of concurrent chemoradiation, mir-
rored those observed by Furuse et al.18 A statistically significant
survival advantage accrued to patients receiving systemic doses
of both cisplatin and vinblastine and concurrent full-dose, once-
daily TRT.19,20
Most trials in locally advanced NSCLC have employed
cisplatin or carboplatin, and this class of agent remains the
backbone of combined-modality therapy. Camptothecin is an
alkaloid obtained from plants such as Camptotheca acumi-
nata. It is a potent inhibitor of topoisomerase 1, a nuclear
enzyme that plays a critical role in DNA replication and
transcription.21–25 Irinotecan has single-agent activity in ad-
vanced NSCLC, and, in combination with cisplatin and other
agents, it has generated response rates and survival times
similar to those from other modern doublets.26–40 In addition,
topoisomerase 1 inhibition can yield radiosensitizing ef-
fects.41 The Japanese have evaluated the role of irinotecan in
combination with TRT, both alone and in combination with
cisplatin.42–45 Generally, they have employed split-course
radiation in an effort to reduce toxicity. Evidence suggests
that scheduled interruptions of radiation (e.g., split course)
can potentially compromise efficacy. Hence, we initiated a
phase I trial of weekly irinotecan and cisplatin in combination
with radiation delivered once daily in a continuous fashion in
an attempt to capitalize on the radiosensitivity and putative
synergy of both systemic agents.
MATERIALS AND METHODS
Objectives
The purpose of this trial was to determine the maxi-
mum-tolerated dose (MTD) of weekly irinotecan and cispla-
tin in combination with standard TRT (63 Gy). Secondary
objectives included toxicity and tolerability of this combina-
tion, with attention to acute and long-term esophagitis and
pneumonitis. In addition, we sought to tabulate response rate,
freedom from progression, survival, and sites of relapse.
Eligibility Criteria
Eligibility stipulated biopsy or cytologically docu-
mented locally advanced stage IIIb or bulky IIIa NSCLC that
was not amenable to surgical resection. Patients with local or
regional recurrence of NSCLC after prior surgery and not
amenable to further surgery were also deemed eligible. Com-
puted tomography (CT)-visible pleural effusions that were
not appreciated on chest x-ray and that were either inacces-
sible to thoracentesis or were cytologically negative were
allowed. Additional eligibility criteria included a minimum
age of 18; Eastern Cooperative Oncology Group (ECOG)
performance status (PS) of 0 or 1; adequate end organ indices
defined as a minimum neutrophil count of 2000, platelet
count of 100,000, bilirubin 1.5 mg/dl, creatinine 1.5
mg/dl, minimum forced expiratory volume in 1 second of 1
liter; no other active, invasive malignancies curatively treated
in the past 3 years; 10% unintended weight loss in the 3
months before diagnosis; social situation favorable to com-
pliance; and pretreatment evaluation by both medical and
radiation oncology, with eligibility agreed on mutually. The
study also required informed consent in accordance with the
regulations of the Fox Chase Cancer Center’s institutional
review board. Exclusion criteria included history of myocar-
dial infarction in the preceding 6 months; symptomatic car-
diovascular disease, including active angina, congestive heart
failure, or uncontrolled arrhythmias; other concomitant med-
ical conditions precluding aggressive treatment; evidence of
disease beyond a single radiation portal (e.g., pleural involve-
ment and/or stage IV disease); mixed small cell/non-small
cell histology; positive human chorionic gonadotropin in
women of child-bearing age; prior chemotherapy and/or ra-
diation for this diagnosis; prior chest radiation; prior exposure
to irinotecan; uncontrolled infections or known HIV infection;
baseline calcium 12 mg/dL; and history of Gilbert’s disease.
Treatment Schema
Full-dose radiation (63 Gy) was employed, with elec-
tive nodal treatment up to 45 Gy. Treatment was delivered in
180-cGy fractions for 25 days, with subsequent boost (18 Gy
in nine fractions at 200 cGy/fx) to the primary, involved
nodes, and to nodes measuring 2 cm. The entire mediasti-
num was treated in all cases. Upper-lobe primaries also
received elective treatment to the ipsilateral supraclavicular
lymph nodes. Contralateral hilar nodes were not treated.
Three-dimensional conformal treatment planning was imple-
mented. The maximum dose to the spinal cord was 45 Gy.
Radiation was delivered in accordance with Radiation Ther-
apy Oncology Group guidelines. There were no formal radi-
ation dose modifications for toxicity (Figure 1).
Cisplatin was administered weekly for 7 weeks during
radiation at a dose of 25 mg/m2 in 500 to 1000 ml of normal
saline or half-normal saline. Patients received prehydration
with a minimum of 1 liter of intravenous fluids; posthydration
consisted of a minimal additional 1 liter of fluid, with man-
nitol and furosemide at the discretion of the prescribing
physician.
Irinotecan was administered at an initial dose of 30
mg/m2 for 60 to 90 minutes in 500 ml of dextrose 5% in
water; these doses were administered weekly, immediately
before cisplatin, and they were generally piggybacked to
prehydration. The cisplatin dose was kept fixed, and the
irinotecan dose was escalated across sequential cohorts from
30 to 40 mg/m2 and, ultimately, to 50 mg/m2 per week. There
FIGURE 1. Treatment schema for the study.
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were no formal plans to give chemotherapy either before or
after concurrent chemoradiation.
Treatment Modifications
On the day of treatment, irinotecan was administered at
full dose if the absolute neutrophil count was 1250 or higher
and if the platelet count was 75,000 or higher. The dose was
reduced by 50% for absolute neutrophil counts of 750 to 1249
or for platelet counts of 50,000 to 75,000. In the absence of
radiation interruption, there were no plans to make up missed
doses of irinotecan. Cisplatin was withheld on days that
irinotecan was withheld. The cisplatin dose was reduced by
50% for serum creatinine levels of 1.6 to 2 mg/dl and was
withheld for creatinines of more than 2 mg/dl. Grade 2
neurotoxicity mandated 50% dose reduction. Grade 3 and 4
neurotoxicity mandated suspension of cisplatin. Neutropenic
fever dictated a permanent 25% dose reduction of both
agents.
Diarrhea was managed supportively with aggressive
use of diphenoxylate or loperamide. Grade 4 diarrhea man-
dated a permanent 50% reduction of the irinotecan dose. In
the face of grade 3 or 4 esophagitis, both agents were
withheld. Once esophagitis improved to grade 2 or lower,
each agent was reduced by 25%.
Finally, for attributable nonhematologic grade 3 or 4
toxicity, excluding nausea, vomiting, or alopecia, both agents
were withheld until recovery to a status of grade 1 or lower,
with a subsequent, mandatory 25% dose reduction during the
ensuing weeks of therapy. Supportive therapy included the
use of loperamide or diphenoxylate sodium for irinotecan-
induced diarrhea and atropine at the package insert dose of
0.25 to 1 mg for lacrimation, diaphoresis, abdominal cramp-
ing, diarrhea, or other symptoms of early cholinergic syn-
drome induced by irinotecan. In addition, standard 5-HT3
inhibitors (e.g., ondansetron or granisetron) were employed
before cisplatin. Additional antiemetics were prescribed at
investigator’s discretion.
Growth factor support was strictly prohibited during
radiation.
Criteria for Removal from Study
Patients were removed from treatment in the face of
unacceptable toxicity, documented disease progression, con-
sent withdrawal, or other changes in patient condition ren-
dering further treatment unacceptable or unsafe in the judg-
ment of the investigator.
Pretreatment Evaluation and Follow-Up
At baseline, complete medical history and physical
exam, including documentation of height, weight, body sur-
face area, weight loss in the preceding 6 months, ECOG PS,
and tumor measurements, were obtained. The protocol man-
dated a baseline complete blood count with differential and
platelet counts and also baseline serum chemistries and elec-
trolytes, including blood urea nitrogen and creatinine, glu-
cose, magnesium, serum glutamic oxaloacetic transaminase,
serum glutamic pyruvic transaminase, lactate dehydrogenase,
alkaline phosphatase, bilirubin, total protein, albumin, and
calcium, within 3 weeks of protocol initiation. Baseline CT of
the chest and upper abdomen was required within 3 weeks of
protocol initiation. Baseline bone scan and brain scan, either
CT or magnetic resonance imaging, documenting the absence
of metastatic disease, were obtained within 6 weeks of pro-
tocol initiation. Pulmonary function tests and electrocardiog-
raphy also were required within 6 weeks of protocol treat-
ment. In women of child-bearing potential, documentation of
(negative) human chorionic gonadotropin was required
within 2 weeks of treatment.
Statistical Considerations
The phase I endpoint—specifically, the MTD of irino-
tecan, combined with fixed-dose cisplatin and definitive ra-
diation (TRT)—was determined by standard phase I dose
escalation in three- to six-patient cohorts. Dose-limiting tox-
icity (DLT) was defined as grade 4 esophagitis, febrile neu-
tropenia, or any toxicity mandating radiation interruption for
more than 1 week and/or two or more consecutive dose
omissions necessitated by clear-cut toxicity. If no DLT was
elicited in a specific cohort, dose escalation proceeded to the
next level. If one or more of the first three patients in a
specific cohort sustained DLT, accrual in that cohort was
expanded to six or more patients. If two or more DLTs
occurred, accrual to that cohort was suspended and the
preceding dose level was considered the MTD. In this man-
ner, the chance of overescalation when DLT exceeded 50%
was less than 17.2%. We anticipated a minimum accrual of
12 patients and a maximum accrual of 24 patients.
Standard ECOG response criteria were used.
RESULTS
Demographics
During a 2-year period, 15 patients were enrolled
(Table 1). Eight patients were female and seven were male.
The median age was 65 (range, 47–77). Five had stage IIIa
NSCLC, nine had stage IIIb disease, and one had local

















*Mediastinal nodes after prior surgery.
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evidence of distant spread. Eight patients were PS 0, six were
PS 1, and one, after retrospective reassessment, was PS 2.
Dose Escalation
Dose levels are shown in Table 2.
Dose Level 1
One episode of neutropenic fever occurred. This patient
developed precipitous neutropenia in the face of overwhelm-
ing pneumonia during week 4, with no antecedent cytopenia,
prompting emergency hospitalization. Aspergillus pneumoni-
tis was ultimately diagnosed. This patient developed transient
renal insufficiency, with a rise in creatinine from 0.9 to 2.1
mg/dl, but creatinine later normalized to 1.1 mg/dl. Further
protocol therapy for this patient was halted. This patient was
replaced, and the cohort expanded to seven patients. There
were no other grade 4 toxicities. Two of the remaining six
patients who experienced grade 3 neutropenia also experi-
enced grade 2 and 3 esophagitis, respectively. One additional
patient experienced delayed grade 3 pneumonitis after treat-
ment had been completed. This proved reversible with corti-
costeroids. Two of six patients experienced grade 3 fatigue,
and one of six patients experienced grade 3 diarrhea. Maxi-
mum patient-specific toxicities are detailed in Table 3.
Dose Level 2
Irinotecan at a dosage of 40 mg/m2 per week (Table 4),
in combination with 25 mg/m2 of cisplatin per week), proved
to be dose limiting. There was no grade 3 or 4 esophagitis.
Nevertheless, five of seven patients experienced neutropenia
of grade 3 or higher. There was one episode of neutropenic
fever, and another patient required protracted treatment delay
attributable to neutropenia. One of seven patients experienced
grade 3 anemia. There were no other grade 3 or 4 toxicities.
Before it was clear that dose level 2 had yielded
DLT, one patient was enrolled in dose level 3 (50 mg/m2
of irinotecan per week  25 mg/ml2 of cisplatin per week).
This patient experienced grade 4 esophagitis, nausea, vom-
iting, and myocardial infarction, prompting treatment dis-
continuation.
Besides aspergillus pneumonitis in the face of over-
whelming neutropenia, there was one other unexpected ad-
verse event: an elderly patient experienced a left-hemisphere
cerebral vascular accident during week 6 of concurrent ther-
apy, in association with orthostasis and grade 3 nausea and
vomiting. Her gastrointestinal symptoms quickly remitted,
and she subsequently experienced full recovery of her hemi-
paresis.
Dose Delivery
Of seven patients enrolled in cohort 1, the median
number of weeks of treatment was 6 (range, 3–7). Four of
seven patients required dose reductions or omissions, totaling
14% of doses. Targeted dose intensity of irinotecan was 30
mg/m2 per week, and the received dose intensity was 27
mg/m2 per week.
Of seven patients enrolled in cohort 2, the median
number of doses was 6 (range, 5–7). Six of seven patients
(86%) required dose reductions or omissions, during 30% of
treatment cycles. The targeted dose intensity (Table 5) was 40
TABLE 2. Dose Levels (mg/m2)
Level Irinotecan Cisplatin n
1 30 25 7
2 40 25 7
3* 50 25 1
*Accrual at this dose level was aborted after one patient had nausea, vomiting,
dehydration, and myocardial infarction.
TABLE 3. Maximum Patient-Specific Toxicities: Dose Level
1 (n  7)
Grade 0 1 2 3 4
Esophagitis 3 2 1 1 0
Pneumonitis 5 1 0 1 0
Neutropenia 0 3 1 2 1*
Anemia 3 0 4 0 0
Thrombocytopenia 4 2 1 0 0
Fatigue 2 1 2 2 0
Nausea or emesis 2 3 2 0 0
Diarrhea 5 0 1 1 0
*One episode of neutropenic fever.
TABLE 4. Maximum Patient-Specific Toxicities: Dose Level
2 (n  7)
Grade 0 1 2 3 4
Esophagitis 0 3 4 0 0
Pneumonitis 7 0 0 0 0
Neutropenia 0 1 1 3* 2*
Anemia 0 3 3 1 0
Thrombocytopenia 5 1 1 0 0
Fatigue 0 5 2 0 0
Nausea or emesis 1 2 4 0 0
Diarrhea 2 3 2 0 0
*Dose-limiting toxicity included (1) neutropenic fever, (2) protracted treatment
delay because of neutropenia, and (3) grade 4 esophagitis, seen in one patient at dose
level 3.
TABLE 5. Dose Delivery (n  14)
Cohort 1 Cohort 2
Total no. of patients 7 7




No. of patients 4 (57%) 6 (86%)
No. of cycles 6 (14%) 13 (30%)
Targeted dose intensity (mg/m2) 30 40
Received dose intensity (mg/m2) 27 32.5
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mg/m2 per week; the received dose intensity was only 32.5
mg/m2 per week (81.25% versus 90% for cohort 1).
Hence, the MTD for weekly irinotecan in combination
with 25 mg/m2 of cisplatin and full-dose radiotherapy (63
Gy) was 30 mg/m2.
Response and Survival Analyses
At a median potential follow-up of 62 months, four
patients remain alive for more than 3 years, three with
evidence of progression (Figure 2). One remains free of
relapse at 6 years. The median survival is 28 months (95%
confidence interval, 10 months, not reached).
Four patients experienced no progression whatsoever;
six experienced local regional progression, four experienced
distant progression, and one experienced both local and
distant progression. There were three complete responses,
eight partial responses, one patient with stable disease, and
one with progressive disease. Two patients were removed
from the study because of adverse events or toxicity.
DISCUSSION
Concurrent chemoradiation with weekly irinotecan and
cisplatin is active and feasible in locally advanced, unresect-
able NSCLC. In combination with 25 mg/m2 of cisplatin per
week and TRT (63 Gy), the MTD of irinotecan in this setting
is 30 mg/m2 per week. This combination was well tolerated,
with acceptable esophagitis and no significant attributable
pneumonitis. Moreover, response rate and survival seem
promising. Irinotecan doses of 40 to 50 mg/m2 per week,
using this schedule, resulted in dose-limiting myelosuppres-
sion and esophagitis.
By incorporating uninterrupted RT, the standard in the
United States, our regimen distinguishes itself from many of
the Japanese phase I evaluations of this combination that have
typically employed split-course RT.43,44 Choy and colleagues
mounted a similar phase I study of irinotecan, first alone, then
in combination with carboplatin (area under the curve [AUC]
2) in combination with TRT.46,47 Twenty-seven patients were
accrued to this effort. DLTs—specifically, esophagitis and
nausea and vomiting—were observed at an irinotecan dose of
50 mg/m2 per week. The MTD for single-agent irinotecan
was 40 mg/m2; in combination with weekly carboplatin
(dosed to a targeted AUC of 2), it was identical to the MTD
we observed (30 mg/m2). The overall response rate was 65%.
The results of both the Fox Chase effort and the
Vanderbilt effort suggest that irinotecan can be combined
safely with either carboplatin or cisplatin on a weekly basis,
without compromising radiation dose or acceptable standards
of safety. Esophagitis, pulmonary toxicity, and neutropenia
are the main side effects, but in combination with cisplatin at
25 mg/m2 per week or carboplatin (AUC 2 weekly), an
irinotecan dose of 30 mg/m2 per week seems both safe and
manageable. The response rates and the 1- and 2-year sur-
vival rates observed in these studies are encouraging. Ran-
domized phase III efforts are needed to compare irinotecan
against other agents in this setting. In the absence of signif-
icant esophagitis, one can consider dose escalation of RT
with conformal therapy, an approach employed in studies
evaluating paclitaxel, carboplatin, and RT.
The Japanese Experience
Tamura and colleagues41 showed that irinotecan could
heighten radioresponsiveness in human lung tumor xeno-
grafts in mice. Takeda et al.42 mounted a phase I study of
weekly irinotecan combined with standard TRT. Irinotecan
was escalated across sequential cohorts, starting at 30 mg/m2
and going up by 15 mg/m2 per cohort to a maximum dose of
75 mg/m2. Twenty-six patients (20 men and 6 women) were
accrued; median age was 63, and 22 of 26 patients were PS
0 or 1. All but one had stage IIIb disease. Sixteen patients had
squamous cell histology. DLT was observed at 60 mg/m2; at
this dose, three of five patients experienced grade 3 or 4
esophagitis or pulmonary toxicity. The recommended dose
was 45 mg/m2 per week. The overall response rate was 77%,
and the 1-year survival rate was 61.5%. The median survival
time in this phase I effort was 15.7 months and matched
survival times observed in cooperative group studies with far
more toxic high-dose platinum and vinblastine.
Oka et al.43 combined split-course radiation with two
cycles of 60 to 80 mg/m2 of cisplatin and 40 to 60 mg/m2 of
irinotecan on days 1, 8, and 15. The respective MTDs were
80 and 60 mg/m2. Radiation was given to a total dose of 24
Gy for day 1, cycle 1; after a 2-week split, 26 to 38 Gy was
administered for cycle 2. Twenty-three patients were accrued.
Four patients experienced esophagitis of grade 2 or higher.
The overall response rate was 70%, and the median survival
time was approximately 1 year.
Another trial combined standard TRT, carboplatin, and
irinotecan.44 Thirty-one patients were accrued, 24 of whom
were male. Median age was 62. All but two patients were PS
0 or 1. Eighteen of 30 evaluable patients had stage III disease.
Nineteen patients had squamous cell histology. Carboplatin
was administered at a dosage of 20 mg/m2 per day, and
sequential cohorts received escalating doses of irinotecan
each week. Doses of 60 mg/m2 resulted in unacceptable
FIGURE 2. Product limit estimate of survival for all patients.
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toxicity. All three patients at that dose experienced grade 4
pneumonitis. The overall response rate was 60%. Median
survival time was 15.1 months, and the 1-year survival rate
was 56.7%.
Kawahara et al.45 mounted a combination trial that
included induction therapy with irinotecan and cisplatin, and
then concurrent radiation and chemotherapy with irinotecan
alone. Patients received two cycles of full-dose induction: 80
mg/m2 of cisplatin on days 1 and 29, and 60 mg/m2 of
irinotecan on days 1, 8, 15, 29, 36, and 43. TRT was
administered on day 57; 60 Gy were given for six consecutive
weeks, combined with 30 mg/m2 of irinotecan per week for 6
weeks. Cisplatin was not given during RT. Sixty-eight pa-
tients (52 men and 16 women) were enrolled. Median age
was 63. Roughly two thirds were PS 1. Forty patients had
stage IIIb disease; 33 had squamous cell histology, and 34
had adenocarcinoma. The total incidence of grade 3 and 4
toxicities during induction chemotherapy was predictable:
neutropenia occurred in 72%, and diarrhea occurred in 29%.
Grade 3 and 4 toxicities during concomitant TRT and irino-
tecan consisted of neutropenia in 18%, esophagitis in 4%, and
hypoxemia in 6%. There were no treatment-related deaths.
The overall response rate was 64%. Median survival time was
reasonable at 16.5 months; the 1-year survival rate was
65.8%, and the 2-year survival rate was 32.9%.
These efforts do not necessarily distinguish irinotecan
from other cytotoxics in this setting, but they clearly demon-
strate that topoisomerase I inhibition, either alone or in combi-
nation with platinating agents, has a potential role with radiation.
Whether phase III studies bear out a survival benefit or a more
favorable therapeutic index, vis a vis toxicity, remains to be
seen. We would propose studies comparing this regimen against
etoposide and cisplatin in combination with TRT. Although
etoposide is commonly used in this setting, it is a relatively weak
radiosensitizer compared with irinotecan. Determining whether
irinotecan and cisplatin should be administered in the neoadju-
vant or consolidation setting will require additional trials.
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